reverse cholesterol transport, phase 2 b trials announced in June, hit 2 year high today, look at the chart on this. Phase 2 passes it will be the first drug to reduce plaque meaningfully with reverse cholesterol transport. Could be the next IDB Pharmaceuticals which went from 4 to 40 before taken out by Astra Zeneca. 250 m market cap, revolutionary drug for atheroscolosis, a 1 B buy out is a triple to 14 dollars on phase 2. After Phase 3 could be 45.